Hypersence Data Room
Declining brain health has become a global epidemic since Covid. As a result, one in 6 people around the world are suffering from reduced mental function. We’re bringing a groundbreaking solution to millions with our patent-pending, AI-powered MemorySPEX. We plan on going to market as an FDA “General Wellness” product, then filing as a predicate device for the treatment of Alzheimer’s. We’re raising a $750K seed round, forecasting a multi-billion dollar exit. Want to learn even more? Schedule a meeting with the team https://calendly.com/kimlavine
MemorySPEX by Hypersence is pioneering a groundbreaking approach to cognitive health through non-invasive brainwave stimulation, specifically targeting gamma oscillations.
Supporting Scientific Research
The efficacy of MemorySPEX technology is rooted in gamma oscillation entrainment, a process that has been shown in multiple studies to:
Prevent neuronal loss and protect synaptic connections in the brain.
Reduce amyloid plaques and tau protein buildup associated with Alzheimer’s disease.
Increase microglial activity, which helps clear waste products from the brain.
Improve sleep quality, enhancing immune response, stress management, and overall cognitive performance.
Key studies from reputable institutions such as MIT and Georgia Tech have validated the potential of gamma oscillation therapy to preserve brain health and improve cognitive outcomes. Please see our RESEARCH page for links to clinical studies.
Value Proposition of MemorySPEX
MemorySPEX represents a non-invasive, cost-effective alternative to current pharmaceutical interventions for cognitive decline. Unlike drugs that have shown limited success and significant side effects, MemorySPEX offers:
A safe, digital therapeutic solution that entrains the brain’s natural gamma oscillations through visual and auditory stimulation.
Potential to prevent cognitive decline in both early and later stages of neurodegenerative diseases.
Scalability across consumer, military, and medical markets.
The technology’s ability to reduce neural inflammation, improve brain blood flow, and enhance sleep makes it a promising solution for addressing not only Alzheimer’s disease but also broader cognitive performance challenges.
Investing in MemorySPEX is investing in the future of cognitive health, providing a cost-effective, non-invasive alternative to traditional pharmaceuticals while addressing one of the most pressing global healthcare challenges of our time.
MemorySPEX has all the key elements for a billion dollar exit:
Patent-pending technology
Multi-billion global market
Wide demographic appeal
World-class team
Decades of science validated by clinical trials
Because of Covid, the world is experiencing a historic brain health crisis. The only solution until now has been brain health supplements, which have no independent clinical proof they work. Despite this, popular supplements like Prevagen and Neuriva are a $14B annual market in the U.S. alone.
Our MemorySPEX exploits this new exploding consumer need by offering safe, non-invasive wearable tech that improves brain function more effectively and at less cost than unproven supplements. Now, as easy as putting on glasses, users can gain competitive advantage at work and school by improving cognitive function up to 50%, with our patent-pending MemorySPEX.
Don’t just take our word for it. We won Stanford’s “Chairman’s Choice” award, competing with startups from around the world. We already have a major national retailer with 10,000 stores interested in MemorySPEX for their stores and also possibly investing at Series A.
We’re raising a $750k seed round, forecasting a multi-billion dollar exit, and just closed an investment with a global VC based in Canada. Want to learn more? Watch this 3-minute video above and join us before it’s too late.
Ready to talk? Use my Calendly link to schedule a time that works for you: https://calendly.com/kimlavine
Thank you for your interest in investing in Hypersence. Please let me know if you have any questions by either calling me at 616-502-7296, or emailing me at kim@hypersence.com to get investment documents.
Thanks again and looking forward to an exciting and profitable future!
Kim Lavine
DUE DILIGENCE MATERIALS
Dr. Jay Salimath analysis of supporting research for MemorySPEX
(email me at kim@hypersence.com for the forecast in Excel format.)
FDA General Wellness Policy for Low Risk Devices
The information contained herein is not an offer to sell, or a solicitation of an offer to buy, any securities and is qualified in its entirety by the more complete information, including risks of investment, provided by Hypersence, in its sole discretion, to certain qualified investors who meet certain investor criteria. There is no assurance that we will achieve any of our investment objectives, and investment results may vary substantially over time.